Zevra Therapeutics: Founder‑Style Exit, CEO Buys More Shares—A Quiet Rebalancing or a Pre‑Funding Signal?
Explore Zevra Therapeutics’ insider moves: LaDuane’s rebalancing, CEO buying, and clinical‑pipeline implications for investors.
3 minutes to read